Avoro Capital Advisors DYN Position
Exited12-Fund ConvergenceAvoro Capital Advisors exited their position in Dyne Therapeutics Inc. (DYN) in Q4 2024, after holding the stock for 3 quarters.
The position was first reported in Q2 2024 and has been tracked across 3 quarterly 13F filings.
DYN is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for DYNE-101 in 837 days (Jul 31, 2028), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 12.7% of float with 8.1 days to cover, indicating significant bearish positioning against the stock.
1 insider purchase totaling $34K has been filed in the last 90 days, providing an additional conviction signal.
About Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Full company profile →Short Interest
12.7%
8.1 days to cover
Insider Buys (90d)
1
$34K total
Avoro Capital Advisors DYN Position History
Frequently Asked Questions
Does Avoro Capital Advisors own DYN?
No. Avoro Capital Advisors exited their position in Dyne Therapeutics Inc. (DYN) in Q4 2024. They previously held the stock for 3 quarters.
How many hedge funds own DYN?
12 specialist biotech hedge funds currently hold DYN, including RTW Investments, RA Capital Management, Deep Track Capital and 9 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy DYN?
Avoro Capital Advisors's position in DYN was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's DYN position increasing or decreasing?
Avoro Capital Advisors completely exited their DYN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DYNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →